Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s blockbuster shots.

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral weight loss drug orforglipron—that helped patients shed weight and control blood sugar,

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its oral weight-loss drug, orforglipron. With a market cap of $796 billion, LLY is the world’s most valuable healthcare company, and its trajectory suggests it could reach $1,000 per share or more by year-end 2025.